Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


Study Shows COVID 'Cocktail' Discovered at VUMC Protects Chronically Ill


 
James Crowe Jr., MD

A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77 percent, the company announced in late August.

Based on the positive results from the PROVENT Phase III trial, AstraZeneca will seek regulatory approval for AZD7442, a combination of two long-acting antibodies, as a one-dose, pre-exposure prophylaxis that for chronically ill people might be more effective than a vaccine.

AZD7442 is the first antibody combination (non-vaccine) modified to potentially provide long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial, company officials said. The trial included more than 5,000 participants, and more than 75 percent had conditions that can cause a reduced immune response to vaccination.

Delivered by intramuscular injection, the antibody treatment was well tolerated with only minor side effects and could afford up to 12 months of protection from COVID-19, according to officials. Preliminary laboratory findings also suggest that AZD7442 can neutralize recent emergent variants of the virus, including the delta variant.

"It's deeply gratifying to see the antibodies we isolated under challenging circumstances, in the middle of the international lockdown last spring, protecting the most vulnerable amongst us," said James Crowe Jr., MD, director of the Vanderbilt Vaccine Center who led the VUMC research effort. "This single-shot prevention is likely to be a game changer for at-risk patients."

"The near-term availability of AZD7442 comes at an opportune time," added Robert Carnahan, PhD, associate director of the Vanderbilt Vaccine Center. "It is clear that we need additional solutions beyond vaccines to protect those most vulnerable members of our society, such as the immunocompromised." He added, "These studies specifically targeted patients with comorbidities where interventions beyond a vaccine are warranted."

The original antibodies that were the basis for the engineered long-acting antibodies that make up the AZD7442 two-antibody cocktail were isolated last year at VUMC. Crowe and his colleagues have developed ultra-fast methods for discovering highly potent antiviral human monoclonal antibodies and validating their ability to protect small animals and non-human primates.

Six of the antibodies were licensed to AstraZeneca in June for advancement into clinical development. In October the company announced it was advancing into Phase III clinical trials an investigational therapy consisting of two long-acting antibodies discovered at VUMC and optimized by AstraZeneca.

The VUMC research was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, the Defense Advanced Research Projects Agency of the U.S. Department of Defense, the Dolly Parton COVID-19 Research Fund at Vanderbilt, and Merck KGaA, Darmstadt, Germany.

WEB:

AstraZeneca Announcement

 
Share:

Related Articles:


Recent Articles

New Study Identifies Gaps in Treatment for Opioid Use Disorder as Overdose Emergencies Soar

Opioid overdose deaths have reached record highs and emergency physicians have a vital role in potentially saving these patients by prescribing Medication Assisted Treatment (MAT) such as buprenorphine, and by prescribing naloxone, a rapid-acting medicine to reverse an overdose.

Read More

HealthStream Acquires Rievent Technologies

Leveraging its hStream open architecture, HealthStream expands its ecosystem with a powerful continuing education management and delivery application

Read More

INTERNATIONAL VOLUNTEER DAY: LOCAL PEDIATRICIAN TERRI WHITE DEDICATES TIME TO HELP CHILDREN WORLDWIDE

International Volunteer Day is a global celebration of volunteers. It takes place every year on December 5 to shine a light on the impact of volunteer efforts everywhere.

Read More

Tivity Health Takes Meaningful Steps to Keep Seniors Engaged, Connected

At first glance, SilverSneakers might appear to be 'just' a fitness class ... but dig a bit deeper, and it's clear this class is actually a community keeping participants active and engaged.

Read More

AMA Adopts Policy to Combat Public Health Disinformation by Health Care Professionals

New policy aims to address spread of rampant disinformation amid COVID-19 pandemic

Read More

AMA Adopts Policy Aimed at Strengthening U.S. Public Health Infrastructure, Opposing Limits Placed on Public Health Officials

New policy calls for consistent, sustainable funding, a robust public health workforce, and data modernization

Read More

Managing Risk of Cyber Incidents

Cyber threats are here to stay -- and they continue to be one of the topics keeping senior management up at night. With breaches and ransomware attacks still occurring at high rates, the healthcare industry continues to be significantly impacted.

Read More

American Cancer Society, Meharry Team Up to Change the Narrative

Meharry Medical College is one of four HBCUs partnering with the American Cancer Society.

Read More

Navigating Cancer Care

Nashville startup Thyme Care is proving to be an innovator in the cancer navigation space.

Read More

ONcology Rounds

New treatments, research and leadership - Middle Tennessee has a lot going on in oncology care.

Read More

Email Print
 
 

 

 


Tags:
AstraZeneca, AZD7442, COVID-19, James Crowe, PROVENT Clinical Trial, Robert Carnahan, Vanderbilt University Medical Center, Vanderbilt Vaccine Center, VUMC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: